Home cannabis Page 2

Keyword: cannabis

21 results found
A look at medical cannabis coverage’s growing pains

After the Arthritis Society’s extensive advocacy for medical cannabis research, it seemed only natural for the organization to cover the drug under its employee benefits plan. In 2017, as it prepared to introduce the coverage, it brought together an expert panel, including doctors with extensive experience prescribing medical cannabis and expert pharmacists and advisors from […]

Fluor Canada shares journey of move to managed drug formulary

Alongside Fluor Canada’s recent move to a flexible benefits plan, it also introduced a managed drug formulary, which includes generic substitution, prior authorization, lifetime maximums and an annual out-of-pocket maximum. While the organization was hesitant to make the change, it knew it was necessary to help control drug costs, said Michelle Ginter, senior human resources […]

Canadian employers want more information about cannabis in the workplace: survey

The vast majority (87 per cent) of Canadian business owners said they haven’t had any cannabis-related incidents in the workplace since recreational cannabis was legalized last October, according to a new survey by the Canadian Federation of Independent Business. Just eight per cent said they had experienced an incident, while five per cent were unsure. Employers with […]

  • By: Staff
  • October 21, 2019 November 12, 2020
  • 10:00
Cannabis companies must address the ‘G’ in ESG to attract institutional investors: panel

Canada’s fledgling cannabis companies should implement strong governance protocols and show they’re attempting to address material environmental and social risks to grow their base of institutional investors. Speaking on Friday at a panel discussion on cannabis companies and governance practices nearly a year after legalization, Michelle de Cordova, a principal at ESG Global Advisors Inc., […]

Majority of Canadians say legalization of recreational pot not impacting workplace: survey

Nearly a year since the legalization of recreational cannabis, most Canadians said it’s hasn’t had an impact at work in terms of health and safety (75 per cent), productivity (74 per cent), absenteeism (71 per cent) or quality of work (70 per cent), according to a new survey by ADP Canada. This is in contrast […]

  • By: Staff
  • October 3, 2019 November 12, 2020
  • 08:50
115448363-123RF

The number of Canadian venture capital deals declined in the first half of 2019, according to research from PwC Canada. The total amount raised by Canadian companies was down 13 per cent for the first six months of the year compared to the same time period in 2018, with the number of deals down by […]

  • By: Staff
  • August 6, 2019 January 9, 2021
  • 07:54
What investment risks remain as the cannabis market grows?

With the legalization of recreational cannabis in Canada and a patchwork of regulations governing its use in various states in the U.S., the sector’s influence is growing, according to new research by MSCI Inc. In total, 50 countries now allow some form of medical cannabis use, while six countries have legalized it recreationally. In terms of public […]

  • By: Staff
  • July 15, 2019 November 12, 2020
  • 15:00
Canopy Growth, CMHA partnership to develop education on cannabis in the workplace

Spectrum Therapeutics, the medical division of Canopy Growth Corp., is partnering with the Canadian Mental Health Association to develop an educational content module related to cannabis in the workplace. The module, which will be part of the CMHA’s workplace mental-health program Not Myself Today, will launch early next year. It will feature a number of physical […]

  • By: Staff
  • July 10, 2019 November 12, 2020
  • 15:10
Conference Coverage: 2019 Chronic Disease at Work

On June 5, Benefits Canada‘s 2019 Chronic Disease at Work conference featured educational presentations around trends and treatments in an effort to help plan sponsors and advisors make the best decisions for their plans and members. Here’s what you missed! Behavioural change a key component to managing chronic disease More than 50 per cent of […]

Plan sponsors, members interested in cannabis, pharmacogenetics: survey

Plan sponsors and members are increasingly interested in making non-core benefits like pharmacogenetic testing and medical cannabis part of their plans, according to the 2019 Sanofi Canada health-care survey.  For pharmacogenetics, 74 per cent of plan members said they’d consent to giving a sample of their DNA so a physician could prescribe the most effective medication […]